氨磺必利与利培酮治疗精神分裂症患者疗效及安全性对照研究  

Efficacy and safety of amisulpride compared with risperidone in schizophrenic patients

作　　者：魏立和[1] 陈景旭[1] 

机构地区：[1]北京回龙观医院,北京100096

出　　处：《世界临床药物》2014年第5期283-286,290,共5页World Clinical Drug

摘　　要：目的探讨氨磺必利与利培酮对精神分裂症患者的疗效及安全性的差异。方法选择北京回龙观医院住院患者60例,分别予氨磺必利(32例)及利培酮(28例)治疗,于治疗前及治疗后分别进行临床疗效与安全性等方面的观察。结果①两组患者治疗前后PANSS总分均差异显著(P<0.05);与利培酮组相比,氨磺必利组患者的阴性症状、抑郁症状及认知功能均明显改善(P<0.05)。②治疗8周末,两组不良反应发生率及心电图QT间期均无显著性差异。结论氨磺必利和利培酮治疗精神分裂症安全有效,在改善阴性症状、抑郁症状、认知功能方面,氨磺必利优于利培酮。Objective To investigate the differences of efficacy and safety between amisulpride and risperidone in schizophrenic patients. Methods Totally 60 patients from Beijing Huilongguan Hospital were divided into amisulpride group（32 cases） and risperidone group（28 cases）. Efficacy and safety were observed before and after treatment. Results ①Compared with baseline, the total score of PANSS had significant difference in both groups（P〈0.05） after the treatment. Compared with risperidone, the negative symptoms, cognitive function and depressive symptoms were improved significantly in amisulpride group（P〈0.05）. ②There were no significant differences on the incidence of adverse reactions and interval of ECG at end point. Conclusion Amisulpride and risperidone are effective and safe in the treatment of schizophrenia.Compared with risperidone, amisulpride is relatively better on improving negative symptoms, depressive symptoms and cognitive function.

关 键 词：氨磺必利 利培酮 疗效 安全性 精神分裂症 

分 类 号：R971[医药卫生—药品] R749.05[医药卫生—药学]